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INVITED COMMENTARY
Jaap Buth, MD, PhD, Eindhoven, The Netherlands
The objectives of this article from Sicard et al are two-fold.
First, it is meant to assess the benefit of elective endovascular
aneurysm repair (EVAR) in patients at high-risk for open surgery
and second, compare the obtained outcomes with those of the
EVAR 2 trial published in The Lancet in 2005.1 The conclusions of
the current article were substantially different from those of the
EVAR 2 report. The authors have made a commendable effort to
explain the differences, and understandably, they try to convince
the reader that their conclusion is the correct one.
What is the nature of the substantial differences in the main
outcome events after EVAR in these two studies? The design of the
current analysis is not straightforward. The baseline patient cohort
came from five commercially sponsored nonrandomized investiga-
tional device exemption (IDE) studies, with inherently several
unknown factors. The selection criteria to include a patient, al-
though not specified, most likely varied between the different
studies. Study protocols from device manufacturers have a natural
tendency to avoid the selection of patients with an increased risk of
postoperative complications, including death. Nevertheless, the
authors were able to identify a group of patients at high operative
risk.
The factors determining high-risk patients were probably not
equally balanced between the different studies, and most impor-
tant, no formal meta-analysis methodology was used. Crude min-
imal criteria, requiring the presence of (only) one comorbidity,
sufficed to define a patient as high risk, which contrasted from the
severity of the requirements for patient enrolment in EVAR 2.2
The reader must be puzzled by finding out that a portion of these
patients received open repair despite being considered unfit for
open surgery. The details of why a patient was allocated to EVAR
or open repair were not specified.
From a design point of view, the EVAR 2 trial is far superior.
Supported by an independent governmental grant and with proper
randomization of a large patient group between treatments, EVAR
2 is supposed to provide level I scientific evidence. The details were
less transparent, however, and the fact that to date no straightfor-
ward generally accepted criteria exist to define the patient unfit for
open repair caused some confusing observations.
In addition, some disturbing logistic problems occurred dur-
ing the trial. Notably, the significant delay between randomization
and treatment was at the expense of several ruptured aneurysms
before the intervention. All weaknesses were detailed in the discus-
sion of the present article. One of the other flaws in EVAR 2 was
that a number of patients initially were misclassified, as these
patients (crossing-over from watchful waiting to intervention) did
tolerate a secondary AAA procedure well, including open repair in
12 patients.
Where does this leave us? After careful studying the present
article in this journal and the report in The Lancet, it occurs that
there is more than one category of high-risk patients. Considering
the substantial difference in all-cause mortality after 4 years of
follow-up, the average patient in the IDE studies was not nearly as
unfit as most of the patients in EVAR 2. One should note that in
unfit patients, not only the all-cause mortality but also the aneu-
rysm-relatedmortality (including the one-month rate) proportion-
ally increases.3 Perhaps the severest problem of EVAR 2 was that
many patients were too sick for even an endovascular procedure.
What can we learn from these two articles? For intermediately
increased-risk patients, who represent large proportion in the
average vascular surgical practice, the conclusions of the IDE
derived data that EVARmay be the best treatment can be accepted.
In patients with a very short life expectancy, for instance 1 year,3
a policy of nonintervention, as suggested by the EVAR 2 reporters,
definitely is the wiser option.
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